文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

针对 SARS-CoV-2 的免疫显性和中和线性表位。

The immunodominant and neutralization linear epitopes for SARS-CoV-2.

机构信息

National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, China; Innovation Academy for Green Manufacture, Chinese Academy of Sciences, Beijing 100190, China.

Second Department of Internal Medicine, Shijiazhuang Fifth Hospital, Shijiazhuang 050021, China.

出版信息

Cell Rep. 2021 Jan 26;34(4):108666. doi: 10.1016/j.celrep.2020.108666.

DOI:10.1016/j.celrep.2020.108666
PMID:33503420
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7837128/
Abstract

Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are under development, the antigen epitopes on the virus and their immunogenicity are poorly understood. Here, we simulate the 3D structures and predict the B cell epitopes on the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 using structure-based approaches and validate epitope immunogenicity by immunizing mice. Almost all 33 predicted epitopes effectively induce antibody production, six of these are immunodominant epitopes in individuals, and 23 are conserved within SARS-CoV-2, SARS-CoV, and bat coronavirus RaTG13. We find that the immunodominant epitopes of individuals with domestic (China) SARS-CoV-2 are different from those of individuals with imported (Europe) SARS-CoV-2, which may be caused by mutations on the S (G614D) and N proteins. Importantly, we find several epitopes on the S protein that elicit neutralizing antibodies against D614 and G614 SARS-CoV-2, which can contribute to vaccine design against coronaviruses.

摘要

虽然针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的疫苗正在开发中，但人们对该病毒的抗原表位及其免疫原性知之甚少。在这里，我们使用基于结构的方法模拟了 SARS-CoV-2 的刺突 (S)、包膜 (E)、膜 (M) 和核衣壳 (N) 蛋白的 3D 结构，并通过免疫小鼠来验证表位的免疫原性。几乎所有预测的 33 个表位都能有效地诱导抗体产生，其中 6 个是个体中的免疫优势表位，23 个在 SARS-CoV-2、SARS-CoV 和蝙蝠冠状病毒 RaTG13 中保守。我们发现，具有国内 (中国) SARS-CoV-2 的个体的免疫优势表位与具有进口 (欧洲) SARS-CoV-2 的个体的免疫优势表位不同，这可能是由于 S (G614D) 和 N 蛋白的突变所致。重要的是，我们在 S 蛋白上发现了几个能诱导针对 D614 和 G614 SARS-CoV-2 的中和抗体的表位，这有助于针对冠状病毒的疫苗设计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/697b7588ef98/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/36e25806aaf8/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/a8bca08ee8aa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/23df926b835c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/697b7588ef98/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/36e25806aaf8/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/a8bca08ee8aa/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/23df926b835c/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1ad7/7837128/697b7588ef98/gr3_lrg.jpg

相似文献

[1]
The immunodominant and neutralization linear epitopes for SARS-CoV-2.

Cell Rep. 2021-1-26

[2]
COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.

Hum Vaccin Immunother. 2021-4-3

[3]
Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.

Virus Res. 2020-7-1

[4]
Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.

Front Immunol. 2021

[5]
Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.

Front Immunol. 2020-10-28

[6]
Immunodominant linear B cell epitopes in the spike and membrane proteins of SARS-CoV-2 identified by immunoinformatics prediction and immunoassay.

Sci Rep. 2021-10-14

[7]
Deciphering the Role of Humoral and Cellular Immune Responses in Different COVID-19 Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters.

Viruses. 2021-11-16

[8]
Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19.

Front Immunol. 2021

[9]
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).

Pediatrics. 2020-9-2

[10]
In silico discovery of antigenic proteins and epitopes of SARS-CoV-2 for the development of a vaccine or a diagnostic approach for COVID-19.

Sci Rep. 2020-12-28

引用本文的文献

[1]
Pan-Variant SARS-CoV-2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes.

Adv Sci (Weinh). 2025-4

[2]
M protein ectodomain-specific immunity restrains SARS-CoV-2 variants replication.

Front Immunol. 2024

[3]
Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

NPJ Vaccines. 2024-9-9

[4]
Bioinformatic elucidation of conserved epitopes to design a potential vaccine candidate against existing and emerging SARS-CoV-2 variants of concern.

Heliyon. 2024-7-23

[5]
VOE: automated analysis of variant epitopes of SARS-CoV-2 for the development of diagnostic tests or vaccines for COVID-19.

PeerJ. 2024

[6]
An Overview of Recent Developments in the Application of Antigen Displaying Vaccine Platforms: Hints for Future SARS-CoV-2 VLP Vaccines.

Vaccines (Basel). 2023-9-20

[7]
The instantly blocking-based fluorescent immunochromatographic assay for the detection of SARS-CoV-2 neutralizing antibody.

Front Cell Infect Microbiol. 2023

[8]
Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.

Front Immunol. 2023

[9]
Molecular mimicry and autoimmunity in the time of COVID-19.

J Autoimmun. 2023-9

[10]
Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies.

Viruses. 2023-5-26

本文引用的文献

[1]
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.

Nature. 2020-7-30

[2]
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.

Cell. 2020-7-3

[3]
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.

Cell. 2020-6-24

[4]
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.

Science. 2020-6-22

[5]
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.

Immunity. 2020-6-8

[6]
Human neutralizing antibodies elicited by SARS-CoV-2 infection.

Nature. 2020-5-26

[7]
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.

Immunity. 2020-5-3

[8]
SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate.

Int J Clin Pract. 2020-6-3

[9]
Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2.

J Hum Genet. 2020-5-6

[10]
A human monoclonal antibody blocking SARS-CoV-2 infection.

Nat Commun. 2020-5-4

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索